Blood:E3连接酶UBR5突变调控淋巴瘤B细胞成熟

2020-05-03 QQY MedSci原创

利用一种模拟MCL患者突变的新型小鼠模型,发现UBR5 HECT结构域缺失可导致B细胞发育异常。 UBR5突变导致UBR5和剪接体成分的不稳,从而导致剪接异常。

为了促进B细胞发育、激活和存活,需要多种分子机制的协调,包括转录、选择性剪接和类开关重组。这些通路被破坏可导致恶性转化。近期,研究人员通过二代测序在套细胞淋巴瘤(MCL)患者中发现了一些新的突变,包括泛素E3连接酶UBR5突变。

大约18%的MCL患者被发现携带UBR5突变,其中大多数突变发生在蛋白的HECT结构域;该结构域可接受泛素分子并将其转移到底物上。

明确UBR5是否调控了B细胞的成熟对于全面了解MCL的恶性转化具有重要意义。为了阐明UBR5在B细胞成熟和活化中的作用,研究人员建立了一种条件性破坏UBR5的C末端HECT结构域的小鼠模型。结果发现,UBR5 HECT结构域缺失导致导致脾脏B细胞成熟受阻,并通过剪接体上调了与mRNA剪接相关的蛋白。

综上所述,本研究揭示了UBR5在B细胞成熟中的新功能,即在B细胞发育过程中,通过稳定剪接体成分来调控B细胞的成熟,提示UBR5突变在套细胞淋巴瘤转化中具有一定作用。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2030529, encodeId=86a12030529a2, content=<a href='/topic/show?id=b602640e6e' target=_blank style='color:#2F92EE;'>#E3连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6407, encryptionId=b602640e6e, topicName=E3连接酶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Dec 28 14:48:48 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780488, encodeId=74431e8048817, content=<a href='/topic/show?id=96c3384e46' target=_blank style='color:#2F92EE;'>#B细胞成熟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3847, encryptionId=96c3384e46, topicName=B细胞成熟)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Aug 01 01:48:48 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977922, encodeId=d47a19e79220b, content=<a href='/topic/show?id=95f21806615' target=_blank style='color:#2F92EE;'>#UBR5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18066, encryptionId=95f21806615, topicName=UBR5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sat Jan 02 10:48:48 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023415, encodeId=f5f6202341570, content=<a href='/topic/show?id=16639453872' target=_blank style='color:#2F92EE;'>#连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94538, encryptionId=16639453872, topicName=连接酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Aug 04 17:48:48 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 05 05:48:48 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2030529, encodeId=86a12030529a2, content=<a href='/topic/show?id=b602640e6e' target=_blank style='color:#2F92EE;'>#E3连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6407, encryptionId=b602640e6e, topicName=E3连接酶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Dec 28 14:48:48 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780488, encodeId=74431e8048817, content=<a href='/topic/show?id=96c3384e46' target=_blank style='color:#2F92EE;'>#B细胞成熟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3847, encryptionId=96c3384e46, topicName=B细胞成熟)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Aug 01 01:48:48 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977922, encodeId=d47a19e79220b, content=<a href='/topic/show?id=95f21806615' target=_blank style='color:#2F92EE;'>#UBR5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18066, encryptionId=95f21806615, topicName=UBR5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sat Jan 02 10:48:48 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023415, encodeId=f5f6202341570, content=<a href='/topic/show?id=16639453872' target=_blank style='color:#2F92EE;'>#连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94538, encryptionId=16639453872, topicName=连接酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Aug 04 17:48:48 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 05 05:48:48 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2030529, encodeId=86a12030529a2, content=<a href='/topic/show?id=b602640e6e' target=_blank style='color:#2F92EE;'>#E3连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6407, encryptionId=b602640e6e, topicName=E3连接酶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Dec 28 14:48:48 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780488, encodeId=74431e8048817, content=<a href='/topic/show?id=96c3384e46' target=_blank style='color:#2F92EE;'>#B细胞成熟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3847, encryptionId=96c3384e46, topicName=B细胞成熟)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Aug 01 01:48:48 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977922, encodeId=d47a19e79220b, content=<a href='/topic/show?id=95f21806615' target=_blank style='color:#2F92EE;'>#UBR5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18066, encryptionId=95f21806615, topicName=UBR5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sat Jan 02 10:48:48 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023415, encodeId=f5f6202341570, content=<a href='/topic/show?id=16639453872' target=_blank style='color:#2F92EE;'>#连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94538, encryptionId=16639453872, topicName=连接酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Aug 04 17:48:48 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 05 05:48:48 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
    2021-01-02 hyf028
  4. [GetPortalCommentsPageByObjectIdResponse(id=2030529, encodeId=86a12030529a2, content=<a href='/topic/show?id=b602640e6e' target=_blank style='color:#2F92EE;'>#E3连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6407, encryptionId=b602640e6e, topicName=E3连接酶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Dec 28 14:48:48 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780488, encodeId=74431e8048817, content=<a href='/topic/show?id=96c3384e46' target=_blank style='color:#2F92EE;'>#B细胞成熟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3847, encryptionId=96c3384e46, topicName=B细胞成熟)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Aug 01 01:48:48 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977922, encodeId=d47a19e79220b, content=<a href='/topic/show?id=95f21806615' target=_blank style='color:#2F92EE;'>#UBR5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18066, encryptionId=95f21806615, topicName=UBR5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sat Jan 02 10:48:48 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023415, encodeId=f5f6202341570, content=<a href='/topic/show?id=16639453872' target=_blank style='color:#2F92EE;'>#连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94538, encryptionId=16639453872, topicName=连接酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Aug 04 17:48:48 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 05 05:48:48 CST 2020, time=2020-05-05, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2030529, encodeId=86a12030529a2, content=<a href='/topic/show?id=b602640e6e' target=_blank style='color:#2F92EE;'>#E3连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6407, encryptionId=b602640e6e, topicName=E3连接酶)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/22AEC2EC4805C29C6E1DEE6D888DB41C/100, createdBy=7a322500193, createdName=ms1779634646866130, createdTime=Mon Dec 28 14:48:48 CST 2020, time=2020-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1780488, encodeId=74431e8048817, content=<a href='/topic/show?id=96c3384e46' target=_blank style='color:#2F92EE;'>#B细胞成熟#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3847, encryptionId=96c3384e46, topicName=B细胞成熟)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/101296147/385F510BDFE0F55A4FFDFDFFD9892943/100, createdBy=a3262500163, createdName=siiner, createdTime=Sat Aug 01 01:48:48 CST 2020, time=2020-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1977922, encodeId=d47a19e79220b, content=<a href='/topic/show?id=95f21806615' target=_blank style='color:#2F92EE;'>#UBR5#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=18066, encryptionId=95f21806615, topicName=UBR5)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7d40148, createdName=hyf028, createdTime=Sat Jan 02 10:48:48 CST 2021, time=2021-01-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2023415, encodeId=f5f6202341570, content=<a href='/topic/show?id=16639453872' target=_blank style='color:#2F92EE;'>#连接酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94538, encryptionId=16639453872, topicName=连接酶)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5c0050, createdName=lishiwen, createdTime=Tue Aug 04 17:48:48 CST 2020, time=2020-08-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1273354, encodeId=b4f512e33544b, content=<a href='/topic/show?id=310d383ef5' target=_blank style='color:#2F92EE;'>#B细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3837, encryptionId=310d383ef5, topicName=B细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6eba113, createdName=xiaoyeshuang, createdTime=Tue May 05 05:48:48 CST 2020, time=2020-05-05, status=1, ipAttribution=)]

相关资讯

Blood:CCND2和CCND3可通过劫持免疫球蛋白轻链增强子上调细胞周期蛋白的表达

中心点:在细胞周期蛋白D1-套细胞淋巴瘤中,IG轻链增强子的隐式插入与CCND2和CCND3过表达相关。大部分细胞周期蛋白D1-套细胞淋巴瘤携带CCND2或CCND3重排,而小部分表现为CCNE1和CCNE2上调。摘要:套细胞淋巴瘤(MCL)的特征是他(11;14)(q13;q32)易位,导致细胞周期蛋白D1过表达。但是,现在发现一个细胞周期蛋白D1阴性的MCL(CCND1-MCL)小子集,其大约

Kite向FDA提交第二种CAR-T细胞疗法的申请,以治疗套细胞淋巴瘤

吉利德(Gilead)收购的Kite已向美国食品和药物管理局(FDA)提交了第二种CAR-T疗法KTE-X19的申请,有望成为套细胞淋巴瘤(MCL)的首例细胞疗法。

欧洲药品管理局开始审查Kite的自体CAR-T细胞疗法KTE-X19,用于治疗套细胞淋巴瘤

欧洲药品管理局(EMA)开始审查Gilead子公司Kite的嵌合抗原受体(CAR)T细胞疗法KTE-X19,用于治疗复发或难治性的套细胞淋巴瘤(MCL)成年患者。

MD安德森癌症中心开发的新药物,可有效克服套细胞淋巴瘤对依鲁替尼的耐药性

MD安德森癌症中心的一项研究表明,在该机构开发的小分子药物IACS-10759可能有助于克服套细胞淋巴瘤患者对依鲁替尼治疗的耐药性。目前该研究发表在Science Translational Medicine杂志上。

Blood:I期临床试验:依鲁替尼联合帕博西尼可有效治疗套细胞淋巴瘤

依鲁替尼单药用于既往治疗过的套细胞淋巴瘤(MCL)可获得治疗活性;但是,近一半患者在第一年会治疗失败。Peter Martin等人既往发现口服特异性的CDK4/6抑制剂palbociclib(帕博西尼)诱导的G1早期细胞周期阻滞延长,可克服人原发性MCL细胞和表达野生型BTK的MCL细胞系对依鲁替尼的耐药性。进而开展一I期临床试验评估帕博西尼联合依鲁替尼用于既往治疗过的套细胞淋巴瘤的剂量、安全性和

复发难治套细胞淋巴瘤MCL治疗安全有效

套细胞淋巴瘤(MCL)是侵袭性B细胞非霍奇金淋巴瘤(NHL),标准治疗结果并不令人满意。Bruton酪氨酸激酶(BTK)抑制剂在多个NHL亚型的治疗作用已得到验证。伊布替尼是第一个BTK抑制剂,经FDA批准用于治疗复发难治(R/R)MCL,尽管疗效令人鼓舞,但患者经常出现腹泻、出血和房颤等不良事件。目前认为非特异性的靶选择性(对EGFR、TEC、BMX等的抑制作用)可能与不良事件相关。因此不断尝试